These factors are currently under intense focus in the cancer immunotherapy landscape. It is one of the few malignancies for which incidence approximates prevalence, as patients almost always . Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Of special note are the following publications: To browse the literature, please see the curated list at PubMed. She succeeds Louise Peltier, Vice President of Regulatory Affairs, who retired on August 31, 2022. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. Immunomic Therapeutics, Inc. | LinkedIn The Phase 2 protocol will remain active, the existing Principal Investigators (PIs . ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. immunomic therapeutics crunchbase - xarxacatala.cat GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with Immunomic, Colmmune partner on cancer immunotherapy By The Science Advisory Board staff writers. ITI-1001 GBM - pDNA. Book the hotel with real traveler reviews, ratings and latest pictures of Chinatrust Executive House Hsin-Tien. No.93, Zhongyang Rd., Xindian Dist., New Taipei City 231, Taiwan. Pay, Holidays and PTO appear to be very good. This is the Immunomic Therapeutics company profile. Immunomic Therapeutics, Inc. Biotechnology Research Rockville, MD 2,335 followers A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms Pays for all health and welfare insurance premiums 100%. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. For more information, please visit www.immunomix.com. This employer has not claimed their Employer Profile and is missing out on connecting with our community. Director of Research and Development at Immunomic Therapeutics, Inc. - most recent Rockville, Maryland, United States. Edit Lists Featuring This Company Section, Immunomic Therapeutics to Present at Biotech Showcase 2023. Immunomic Therapeutics (ITI) is a clinical stage biotechnology company pioneering investigational technologies that have the potential to alter how immunotherapy is used for cancer, allergies, and animal health. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Melssen M.,Vaccines targeting helper T cells for cancer immunotherapy. Rockville, Maryland, 20850, United States. This is the Immunomic Therapeutics company profile. The company is developing three small molecule products; its lead development program, IMU-838, a selective . 2016;2016:4857869. Handled COVID very well. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. The Company has built a large pipeline from UNITE with six oncology programs and two allergy programs. January 04, 2023 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that, Vaccine exclusively delivered with the PharmaJet StratisNeedle-free Injection System December 13, 2022 11:00 AM Eastern Standard Time GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet, a company that engineers precision delivery systems that overcome, November 08, 2022 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced, October 10, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today. Clin Cancer Res. We currently have 4 wholly-owned oncology programs, with our lead program in Phase 2 clinical studies for GBM. Our Pipeline | Xilio Therapeutics Description. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. Sia Anagnostou Jan 30, 2015. Su Y et al., Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study. Join to follow . Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. mkemp@immunomix.com Immunomic Therapeutics' investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITI's proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. CONTACT US. Operating Status Active. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. 2015 Mar 19;519(7543):366-9. The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. Preclinical research data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics. Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. 2006 Aug 15;177(4):2265-75. Immunomic Therapeutics General Information. Immunomic Therapeutics - Products, Competitors, Financials, Employees Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform . ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the. Immunomic Therapeutics, Inc. | LinkedIn Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Arruda L.B., et al., Dendritic Cell-Lysosomal-Associated Membrane Protein (LAMP) and LAMP-1-HIV-1 Gag Chimeras Have Distinct Cellular Trafficking Pathways and Prime T and B Cell Responses to a Diverse Repertoire of Epitopes. ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Being able to attract someone with so much collective experience, which has resulted in more than 75 regulatory submissions operating in 125 countries, is a real coup for ITI. Immunomic Therapeutics Announces First Patient Dosed in Phase I While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. 2017 Aug;47:85-92. I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement., I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . In addition, ITI and HLB intend to establish an Asian Brain Cancer Research Center in Seoul that will bring together the worlds leading experts and cutting-edge science to advance research in the GBM field and to deploy ITI-1000 to the Asian population. Missing the target in cancer therapy | Nature Cancer 2003 Sep 26;278(39):37926-36. Copied Careers - Immunomic Therapeutics All content is posted anonymously by employees working at Immunomic Therapeutics. To explore Immunic Therapeutics's full profile, request access. ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. Immunomic Therapeutics Announces Close of $61.3M Financing Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . Hope versus experience in glioblastoma | Evaluate ITI-3000 Merkel Cell Carcinoma - pDNA. ITI-3000 Merkel Cell Carcinoma - pDNA. Immunomic Therapeutics Stock Price, Funding, Valuation, Revenue Prior to joining ITI, Ms. Harrison worked as a consultant for various biotechnology companies focused on oncology and infectious disease, leading client interactions with global regulatory authorities regarding product approvals and regulatory planning and implementation. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. Mitchell D.A.,Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. ITI maintains its headquarters in Rockville, Maryland. Johns Hopkins startups leverage the university's world-class research assets and the innovation infrastructure of FastForward, our company incubation program. Since the Astellas deals, we have nearly doubled our research team to include deeper oncology expertise, including vaccinology, even neoantigen vaccine specialization. The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . Email credentials to careers@immunomix.com. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. 2017 Apr 15;23(8):1898-1909. Pays for all health and welfare insurance premiums 100%. The financing will also enable Immunomic to expand its team and infrastructure to support the future growth of the company. November 20, 2020-- Immunomic Therapeutics (ITI) and CoImmune Therapeutics have entered into a license agreement for ITI to use CoImmune's proprietary dendritic cell process for certain ITI cell therapy vaccine programs. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Our portfolio includes more than 150 disruptive companies in areas ranging from the life sciences to engineering technology and digital health. Phone Number +119196161923. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. The foundation of a successful company is only as strong as the quality of its employee team. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. J Immunol Res. ITI-1000 is currently being investigated in a Phase 2 ATTAC-II trial at UF and Duke. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. In addition, ITI-1001 represents a far more cost-effective approach. Company profile page for Immunomic Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information immunomic therapeutics crunchbase. Global Brain Cancer Market Assessment 2021-2030 - PR Newswire Immunomic Therapeutics Company Profile: Valuation & Investors | PitchBook Phone Number +4989208047700. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. The company was founded in 2005 and is based in Lancaster, Pennsylvania. The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. Our goal is to overcome the limitations of current immuno-oncology therapies by . Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. Rockville's Immunomic Therapeutics Inc. is on track to go public later this year, after Covid-19 threw a wrench in the vaccine maker's initial timeline. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Company Type For Profit. Immunomic Therapeutics Inc - Company Profile and News ITI-1000 GBM - Cell Therapy. Immunomic Therapeutics' continued investment in Process Development provides value in several ways. Find More Contacts for Immunic Therapeutics, Edit Lists Featuring This Company Section, Immunic, Inc. At ITI, our success is based in great part on our ability to attract and retain the best, creative, talented, motivated and productive employees throughout our organization. The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. For consideration, please send your company information, a copy of your standard search agreement, and references to: careers@immunomix.com. Melissa Kemp ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. Katie Pearce. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. Equal Opportunity: ITI is committed to creating a diverse environment and is proud to be an Equal Opportunity Employer. We are a patient advocacy company that understands that patient enrollment in clinical trials is critical to advancements in medicine and patient treatment. Companies. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in this tumor type and others. Teri Heiland - Chief Scientific Officer (CSO) - Immunomic Therapeutics J Biol Chem. Immunomic Therapeutics Announces License Agreement With Lineage Cell ITI-ID Candidate Multiple infectious diseases. Contacts ITI Company Contact: Melissa Kemp mkemp@immunomix.com 301-968-3501 ITI Media Contact: Melody Carey mcarey@rxir.com 917-322-2571